Jefferies Assumes Olema Pharmaceuticals at Buy, Lowers Price Target of $40

Benzinga Newsdesk www.benzinga.com Neutral 59.8%

Neg 0% Neu 59.8% Pos 0%

Jefferies analyst Dennis Ding assumes Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and lowers Price Target of $40.